AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas

May 23, 2022

A nonviral, nonintegrating DNA nanovector platform for the safe, rapid, and persistent manufacture of recombinant T cells

April 14, 2021

A vaccine targeting mutant IDH1 in newly diagnosed glioma

March 23, 2021

K27M-mutant histone-3 as a novel target for glioma immunotherapy

May 12, 2017

A vaccine targeting mutant IDH1 induces antitumour immunity

August 21, 2014


© 2022 Tcelltech GmbH. All rights reserved.

Responsible Provider in accordance with § 5 of the German Telemedia Act (TMG):

Tcelltech GmbH

Cubex One

Franz-Volhard-Straße 5

68168 Mannheim


T + 49 178 730 730 2



Michael Platten, Richard Harbottle, Edward Green, Mathias Turwitt

Commercial register/register number

District Court of Mannheim HRB 745 600

VAT number 

not yet available